PROVIDER OUICK POINTS PROVIDER INFORMATION



December 12, 2018

Pharmacy Update for Praluent[®] (alirocumab) and Repatha[®] (evolocumab)

Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) is committed to providing subscribers with safe, quality, pharmacy care.

Effective January 1, 2019, Blue Cross will no longer cover Praluent[®] (alirocumab) and specific NDCs of Repatha[®] (evolocumab) on the Blue Plus formulary. These products are being removed from the formulary. The new Repatha[®] Sureclick NDCs released on October 25, 2018 and Repatha[®] Pushtronex will be the preferred proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on the formulary. Subscribers must use these preferred Repatha NDCs covered on the formulary or pursue the formulary exception and prior authorization processes for consideration of coverage for Praluent[®] and the Repatha[®] NDCs being removed from the formulary. Participating pharmacies have been notified that they will need to order these specific NDCs for Repatha to avoid disruption for these subscribers.

A summary of the impacted medications and the preferred formulary alternatives are listed below:

Non-Formulary Medications/NDCs	Preferred Alternatives/NDCs
Praluent [®] (alirocumab) 75 MG/ML and 150 MG/ML NDCs: 00024-5901-01, 00024-5901-02, 00024-5902-01, 00024- 5902-02, 00024-5903-01, 00024-5903-02, 00024-5904-01, 00024-5904-02	Repatha [®] (evolocumab) SureClick 140 MG/ML NDC 72511-0760-01
Repatha [®] (evolocumab) 140 MG/ML NDC 55513-0750-01	Repatha [®] (evolocumab) SureClick 140 MG/ML NDC 72511-0760-02
Repatha [®] (evolocumab) SureClick 140 MG/ML NDC 55513-0760-01	Repatha [®] (evolocumab) Pushtronex System 420 MG/3.5ML NDC 55513-0770-01
Repatha [®] (evolocumab) SureClick 140 MG/ML NDC 55513-0760-02	

Products Impacted

This notice applies to the following Minnesota Health Care Programs.

- Families and Children [formerly known as Prepaid Medical Assistance Program (PMAP)]
 - MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

Additional Information

• Subscribers may contact the prescribing provider regarding this benefit change. A new prescription should be submitted for those subscribers who are impacted by this change.

QP101-18

Distribution: Available on providers.bluecrossmn.com. https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications

Continued

• Pharmacies will be notified of this benefit change. Blue Cross has asked them to facilitate this benefit change by helping to obtain new prescription.

Questions?

If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.